Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis

Gastroenterology. 2007 Jan;132(1):282-93. doi: 10.1053/j.gastro.2006.10.014. Epub 2006 Oct 12.

Abstract

Background & aims: The increasing prevalence of nonalcoholic steatohepatitis (NASH) is due to the epidemic of obesity and type 2 diabetes, both of which are associated with insulin resistance.

Methods: To clarify the causal relationship between insulin resistance and the development of NASH, steatohepatitis was induced in obese diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) and nondiabetic control Long-Evans Tokushima Otsuka (LETO) rats by feeding them a methionine and choline-deficient (MCD) diet. Insulin sensitivity of the rats was altered by adding a high-fat (HF) diet or the peroxisomal-proliferator activated receptor-gamma agonist pioglitazone to the MCD diet.

Results: The MCD diet-induced steatohepatitis was accelerated in OLETF rats after 8 weeks. Steatosis preceded inflammation, which led to fibrosis and the development of steatohepatitis. The hepatic gene expression for transforming growth factor-beta, alpha1 procollagen and plasminogen activator inhibitor-1 was up-regulated in OLETF rats compared with LETO rats. The MCD + HF diet further enhanced insulin resistance and led to rapid development of pre-cirrhosis in OLETF rats by increasing the triglyceride pool, activating stellate cells, and up-regulating gene expression for sterol regulatory element-binding protein-1c and fatty acid synthase in the liver. In contrast, pioglitazone attenuated the MCD diet-induced steatohepatitis in OLETF rats but not in LETO rats by reversing the underlying pathogenesis involved in this model through improvement of insulin resistance. These results confirm a link between insulin resistance and the development/progression of steatohepatitis, at least partly via up-regulation of genes for lipogenesis, inflammation, and fibrogenesis, in animal models.

Conclusions: Insulin resistance and/or diabetes may accelerate the entire pathologic spectrum of NASH.

MeSH terms

  • Animal Feed
  • Animals
  • Choline / pharmacology
  • Collagen Type I / genetics
  • Collagen Type I, alpha 1 Chain
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Dietary Fats / pharmacology
  • Disease Models, Animal
  • Fatty Liver / metabolism
  • Fatty Liver / pathology
  • Fatty Liver / physiopathology*
  • Hyperinsulinism / drug therapy
  • Hyperinsulinism / metabolism
  • Hyperinsulinism / physiopathology*
  • Hypoglycemic Agents / pharmacology
  • Insulin Resistance / physiology*
  • Liver / drug effects
  • Liver / pathology
  • Male
  • Methionine / deficiency
  • Methionine / pharmacology
  • Obesity / drug therapy
  • Obesity / metabolism
  • Obesity / physiopathology*
  • PPAR gamma / agonists
  • Pioglitazone
  • Plasminogen Activator Inhibitor 1 / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Inbred OLETF
  • Rats, Long-Evans
  • Sterol Regulatory Element Binding Protein 1 / genetics
  • Thiazolidinediones / pharmacology
  • Transforming Growth Factor beta / genetics
  • Up-Regulation / physiology

Substances

  • Collagen Type I
  • Collagen Type I, alpha 1 Chain
  • Dietary Fats
  • Hypoglycemic Agents
  • PPAR gamma
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Sterol Regulatory Element Binding Protein 1
  • Thiazolidinediones
  • Transforming Growth Factor beta
  • Methionine
  • Choline
  • Pioglitazone